Lampoon
发表于 2025-3-21 17:34:41
书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0828447<br><br> <br><br>书目名称Resistance of Targeted Therapies Excluding Antibodies for Lymphomas读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0828447<br><br> <br><br>
LAST
发表于 2025-3-21 22:12:39
http://reply.papertrans.cn/83/8285/828447/828447_2.png
INERT
发表于 2025-3-22 00:28:56
http://reply.papertrans.cn/83/8285/828447/828447_3.png
ATP861
发表于 2025-3-22 07:30:00
http://reply.papertrans.cn/83/8285/828447/828447_4.png
FLOAT
发表于 2025-3-22 09:01:52
Book 2018resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance..
缩短
发表于 2025-3-22 13:52:19
http://reply.papertrans.cn/83/8285/828447/828447_6.png
Preamble
发表于 2025-3-22 17:44:54
http://reply.papertrans.cn/83/8285/828447/828447_7.png
Additive
发表于 2025-3-22 21:31:50
Proteasome Inhibitors with a Focus on Bortezomib, patients eventually have progressive disease and development resistance to treatment. Multiple unique mechanisms of resistance have been identified, and they are unified by reducing a cell’s sensitivity to endoplasmic reticulum stress either from changes intrinsic to the cancer cell or extrinsic to
Glucocorticoids
发表于 2025-3-23 03:09:49
http://reply.papertrans.cn/83/8285/828447/828447_9.png
GROUP
发表于 2025-3-23 06:59:36
mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents,Ks). Dysregulation of mTOR signaling is associated with the development of cancers, including myeloid and lymphoid malignancies. Here, we will provide a brief overview of mTOR inhibitors and discuss the results obtained using these compounds in hematologic malignancies and especially in lymphomas. M